GSK Plc ended 2023 with a pipeline of 71 vaccines and specialty medicines in clinical development and a forecast for sales of more than £38 billion by 2031 – an upgrade from earlier financial projections. Underlying the forecast are plans for the launch of at least 12 new products from 2025. These are vaccines and medicines in development for infectious diseases, HIV, respiratory diseases and oncology.
